ライフサイエンスコーパス: psychedelic

1 therapies that accompany therapeutic uses of psychedelics.

2 pants for testing the therapeutic effects of psychedelics.

3 e rapid and sustained therapeutic effects of psychedelics.

4 newed interest in the mechanism of action of psychedelics.

5 ntinued precision therapeutic development of psychedelics.

6 oes not generalize to all other serotonergic psychedelics.

7 ics increases under DMT, as with those other psychedelics.

8 ollowing administration of high-dose classic psychedelics.

9 complex mechanisms of action of serotonergic psychedelics.

10 ey answered questions related to past use of psychedelics.

11 relate to subjective and lasting effects of psychedelics.

12 nderlying the potential clinical efficacy of psychedelics.

13 omenology qualitatively similar to classical psychedelics.

14 edatives, stimulants, heroin or opiates, and psychedelics.

15 Here we show that a single dose of the psychedelic 2,5-dimethoxy-4-iodoamphetamine ((+/-)-DOI)

16 Exposure to the psychedelic 2,5-dimethoxy-4-iodoamphetamine (DOI) differ

17 anxiolytic effect evoked by the serotonergic psychedelic 2,5-dimethoxy-4-iodoamphetamine (DOI).

18 regarded as the quintessential contemporary psychedelic [2].

19 Eligible randomised controlled trials of psychedelics (3,4-methylenedioxymethamphetamine (known a

20 Here, we examine psychedelic 5-HT(2A/2C) agonist, DOI, effects on dopamin

21 nnectivity, which inform current theories of psychedelic action.

22 To gain molecular insights into psychedelic actions, we determined the active-state stru

23 n mediates psychedelic effects, prototypical psychedelics activate both 5-HT(2A)-Gq/11 and beta-arres

24 Do psychedelics affect sexual functioning postacutely?

25 nter alia, insufficiently characterized with psychedelic agents.

26 ajor compound classes of psychedelic and non-psychedelic agonists, including a beta-arrestin-biased c

27 The psychedelic alkaloid ibogaine has anti-addictive propert

28 nsfer, resulting in a patchy distribution of psychedelics among species.

29 A recently synthesized psychedelic analog tabernanthalog (TBG) has demonstrated

30 However, identifying next-generation psychedelic analogs with ideal receptor selectivity and

31 ircuit mechanisms underlying the response to psychedelic and antipsychotic drugs might lead to unific

32 inical trial was conducted at the Center for Psychedelic and Consciousness Research at Johns Hopkins

33 tures covering all major compound classes of psychedelic and non-psychedelic agonists, including a be

34 ized by underscoring the differences between psychedelic and nonpsychedelic hallucinogens as well as

35 s related to the opportunities and perils of psychedelic and psychedelic-inspired therapeutics.

36 iven the diverse pharmacological profiles of psychedelics and entactogens, we suggest that their rapi

37 eview, we outline a framework for evaluating psychedelics and non-hallucinogenic serotonin 2A (5-HT(2

38 mTOR and AMPA receptor activation-as classic psychedelics and that TBG-induced cortical spinogenesis

39 g the molecular interactions between various psychedelics and the 5-HT(2A) receptor reveals both comm

40 identified that might be the target both of psychedelics and the atypical and glutamate classes of a

41 onvergent effects also emerge: anaesthetics, psychedelics, and disorders of consciousness can exhibit

42 cognitive and subcortical systems altered by psychedelics are not well understood.

43 pothesis holds that the key facts concerning psychedelics are partially explained in terms of increas

44 ltiple studies now point to the potential of psychedelics as a promising, fast-acting, and long-lasti

45 lic, media, and medical research interest in psychedelics as promising therapeutics for difficult-to-

46 Finally, we discuss the potential of psychedelics as substrates for post-translational modifi

47 underlying neurobiological mechanisms of the psychedelic, as well as the baseline, state.

48 Although published clinical trials of psychedelic-assisted psychotherapy have not incorporated

49 motional significance and lasting effects of psychedelic-assisted psychotherapy.

50 iator of therapeutic effects, evidence-based psychedelic-assisted therapies should include these topi

51 Although psychedelic-assisted therapy commonly produces spiritual

52 nsive understanding of risks associated with psychedelic-assisted therapy is necessary as investigato

53 ance of the subjective experience induced by psychedelic-assisted therapy, but without further cross

54 s may contribute to the clinical benefits of psychedelic-assisted therapy, particularly in cases of p

55 d psychotherapy may be fruitfully applied to psychedelic-assisted therapy.

56 o cell-type-specific circuits to produce the psychedelics' behavioural actions(10).

57 Ayahuasca is a psychedelic beverage of Amazonian indigenous origin with

58 ch in uncovering the therapeutic benefits of psychedelics beyond placebo and expectation effects.

59 Ayahuasca is a natural psychedelic brew, which contains dimethyltryptamine (DMT

60 cted that a majority of states will legalize psychedelics by 2034 to 2037.

61 Ensuring health equity and health justice in psychedelic care delivery and research will require stra

62 ommon and distinct motifs among the examined psychedelic chemotypes.

63 king participants to treatment conditions in psychedelic clinical trials has been largely unsuccessfu

64 porating modified informed consent in future psychedelic clinical trials may improve interpretability

65 The main psychedelic component of magic mushrooms is psilocybin,

66 Enzymes for psychedelic compound biosynthesis are encoded in metabol

67 base is insufficient for FDA approval of any psychedelic compound for routine clinical use in psychia

68 N,N-dimethyltryptamine (DMT), a psychedelic compound identified endogenously in mammals,

69 Psilocybin is a classic psychedelic compound that may have efficacy for the trea

70 chemical design, it is possible to modify a psychedelic compound to produce a safer, non-hallucinoge

71 verging model for the therapeutic effects of psychedelic compounds, highlighting the N-methyl D-aspar

72 The effects of ibogaine-like those of other psychedelic compounds-are long-lasting(2), which has bee

73 As psychedelics continue to garner popular and scientific i

74 Further, the psychedelic drug 2,5-Dimethoxy-4-iodoamphetamine (DOI) i

75 Human and animal studies of psychedelic drug action in the brain have demonstrated t

76 A) receptor and the cerebral cortex in acute psychedelic drug action, but different models have evolv

77 LSD robustly stimulates many surrogates of psychedelic drug actions including head twitches, groomi

78 ted HTR detection system was tested with the psychedelic drug DOI in 5-HT(2A)R-KO mice, and via evalu

79 Although the primary psychedelic drug effects are mediated by the 5-HT(2A) se

80 uation of canonical cortical networks during psychedelic drug effects.

81 ) is a potent, rapid-onset, and short-acting psychedelic drug that has not yet been independently tes

82 als (n = 701) to evaluate the association of psychedelic drug use with schizotypy and evidence integr

83 acid diethylamide (LSD) is the prototypical psychedelic drug, but its effects on the human brain hav

84 ollectively, these results reveal that LSD's psychedelic drug-like actions appear to require BArr2.

85 is a common downstream mechanism underlying psychedelic drug-mediated critical period reopening.

86 assic psychedelic users (n = 18,138) and non-psychedelic drug-using respondents (n = 78,236).

87 B receptor, the first such structure for any psychedelic drug.

88 eceptor densities (the key site of action of psychedelic drugs [4]).

89 It is known that high doses of psychedelic drugs activate autonomic and hormonal stress

90 trongly imply that the subjective effects of psychedelic drugs are caused by decreased activity and c

91 Psychedelic drugs are potent modulators of conscious sta

92 mportant advance in scientific research with psychedelic drugs at a time of growing interest in their

93 the past 15 years showing that ketamine and psychedelic drugs can trigger the growth of dendritic sp

94 erspective, we consider the possibility that psychedelic drugs could have a role in treating cortical

95 canonical cortical network states, and that psychedelic drugs disrupt 5-HT2A-mediated network coupli

96 ceptor to study the activation mechanisms of psychedelic drugs due to its high expression and similar

97 Psychedelic drugs have a long history of use in healing

98 Following decades of prohibition, psychedelic drugs have reemerged as promising therapeuti

99 he literature on the clinical application of psychedelic drugs in psychiatric disorders.

100 Can the use of psychedelic drugs induce lasting changes in metaphysical

101 Emerging evidence suggests that psychedelic drugs may exert some of their long-lasting t

102 Psychedelic drugs produce profound changes in consciousn

103 Classic psychedelic drugs such as psilocybin and lysergic acid d

104 ehavior (HTR) is the behavioral signature of psychedelic drugs upon stimulation of the serotonin 5-HT

105 ere coded by an attorney along 2 axes: which psychedelic drugs would be affected and in what ways (eg

106 (MDMA), best known for their illegal use as psychedelic drugs, are showing promise as therapeutics i

107 Psychedelic drugs, including lysergic acid diethylamide

108 d, decades-long global arrest of research on psychedelic drugs, investigation of psychedelics in the

109 tical mediator of the behavioural effects of psychedelic drugs, uncertainty remains about which aspec

110 critical period is a shared property across psychedelic drugs.

111 basic neurobiology underlying the action of psychedelic drugs.

112 ic LSD and accelerate the discovery of novel psychedelic drugs.

113 frequently seen in self-reports of users of psychedelic drugs.

114 eurons are thought to mediate the actions of psychedelic drugs; the native function of these receptor

115 affectively positive scales of a measure of psychedelic effects (5D-ASC).

116 Psychedelic effects are believed to emerge through stimu

117 Psilocybin's acute psychedelic effects typically became detectable 30-60 mi

118 creased blood pressure, heart rate, anxiety, psychedelic effects, and psychotomimetic effects, which

119 t time the relationship between intensity of psychedelic effects, cerebral 5-HT2AR occupancy and plas

120 LSD induces profound psychedelic effects, including changes in the meaning of

121 though 5-HT(2A) receptor activation mediates psychedelic effects, prototypical psychedelics activate

122 naling and elucidating its potential role in psychedelic effects.

123 identified by searching for terms related to psychedelics (eg, psilocybin, MDMA, peyote, mescaline, i

124 ll other substances (including other classic psychedelics) either shared no association to CUD or con

125 eutic target(7,8), little is known about how psychedelics engage 5-HT(1A) and which effects are media

126 irst English language report on LSD in 1950, psychedelics enjoyed a short-lived relationship with psy

127 vity modulation as an approach to sculpt the psychedelic-evoked neural plasticity.

128 Psychedelics exert unique effects on human consciousness

129 Oceanic Boundlessness (OB) dimension of the psychedelic experience correlated with post-dosing antid

130 iety, concerns regarding the duration of the psychedelic experience produced by psilocybin, associate

131 ychiatric diagnosis that emerged after their psychedelic experience, and anxiety symptoms arose or wo

132 tivity, is thought to be of relevance to the psychedelic experience, mediating both acute alterations

133 t' and is therefore likely to benefit from a psychedelic experience, or at least, less likely to be h

134 e as reward processing, exploration, and the psychedelic experience, over 95% of the serotonin in the

135 and emotions, leading to the characteristic psychedelic experience.

136 anges were strongly linked to the subjective psychedelic experience.

137 nd executive functions to mind-wandering and psychedelic experience.

138 tion of 5-HT2AR is a key determinant for the psychedelic experience.

139 psilocin levels were closely associated with psychedelic experience.

140 phenomenological reports of the intensity of psychedelic experience.

141 activity are relatively preserved during the psychedelic experience.

142 ies individuals employ to navigate difficult psychedelic experiences and their relationship to emotio

143 acco misuse, emerging research suggests that psychedelic experiences may also facilitate beneficial c

144 may underlie the lasting positive effects of psychedelic experiences on mental well-being.

145 participants identified as traumatic during psychedelic experiences, and subsequent psychological ou

146 all reported AEs following high-dose classic psychedelic exposure and confirmatory capture of AEs of

147 resurrected scientific interest in classical psychedelics, few studies have focused on potential harm

148 e, but continued research on the efficacy of psychedelics for the treatment of psychiatric disorders

149 A renewed interest in the use of psychedelics for treating obsessive compulsive disorder

150 ical trials exploring safety and efficacy of psychedelics for treatment-resistant depression and nega

151 Here we used psilocybin, a classic psychedelic found in magic mushrooms, and a task-free fu

152 ethoxy-N,N-dimethyltryptamine (5-MeO-DMT), a psychedelic found in the toxin of Colorado River toads(6

153 nvestigated the pharmacology of 41 classical psychedelics from the tryptamine, phenethylamine, and ly

154 Each category of drug, except psychedelics, had genetic influences unique to itself (i

155 Psychedelics have been used by indigenous cultures for m

156 r mechanistic understanding of the action of psychedelics in health and disease.

157 earch on psychedelic drugs, investigation of psychedelics in the context of psychiatric disorders is

158 n addition to evidence supporting the use of psychedelics in treating alcohol and tobacco misuse, eme

159 present a general new 2D J-resolved method, PSYCHEDELIC, in which all homonuclear couplings are supp

160 ost notable neurophysiological signatures of psychedelics, increased entropy in spontaneous neural ac

161 species were inactive, suggesting a role for psychedelic indolethylamine biosynthesis in toads.

162 teracting with these receptors, serotonergic psychedelics induce alterations in perception, cognition

163 Human neuroimaging studies report that psychedelics induce serotonin-2A receptor-dependent chan

164 At the cellular level, psychedelics induce structural neural plasticity(5,6), e

165 important mechanistic principle underpinning psychedelic-induced altered states.

166 in) 2A receptors (5-HT2ARs) is essential for psychedelic-induced cortical plasticity, but it is curre

167 Classic psychedelic-induced ego dissolution involves a shift in

168 ncreased frontal cortex 5-HT(2A)R density or psychedelic-induced head-twitch behavior in adult MIA of

169 use the same framework to link the suggested psychedelic-induced improvements in creativity with endu

170 ced improvements in creativity with enduring psychedelic-induced improvements in mood.

171 Identifying a translatable biomarker of psychedelic-induced neuroplasticity would enable patient

172 ffects have been assumed to be necessary for psychedelic-induced neuroplasticity, our results shed li

173 is limited meta-analytic data on the risk of psychedelic-induced psychosis in individuals with pre-ex

174 -spiking cells as a cellular trigger for the psychedelic-induced relief of anxiety-like behavior.

175 However, measuring psychedelic-induced structural plasticity in humans has

176 -pharmacological factors that could modulate psychedelic-induced therapeutic responses including set,

177 ere we aim to characterize two brain states (psychedelics-induced and placebo) as captured by functio

178 opportunities and perils of psychedelic and psychedelic-inspired therapeutics.

179 Subjective psychedelic intensity and plasma psilocin levels were me

180 (DMT), a closely related, but faster-acting psychedelic intervention, on mental health outcomes in h

181 ssant effects following an intense but brief psychedelic intervention.

182 tors in shaping the therapeutic potential of psychedelic interventions for impaired cognitive flexibi

183 d twitch responses are low with LSD and this psychedelic is without effects on other surrogates.

184 tryptamine (5-MeO-DMT) is a potent classical psychedelic known to induce changes in locomotion, behav

185 twitch response in C57BL/6J mice, suggesting psychedelic-like activity.

186 the signaling mechanisms of the prototypical psychedelic LSD and accelerate the discovery of novel ps

187 Clinical studies have reported that the psychedelic lysergic acid diethylamide (LSD) enhances em

188 sts the actions of ketamine and serotonergic psychedelics may converge at the dendrites, to both enha

189 Emerging evidence suggests that classical psychedelics may offer therapeutic potential for opioid

190 c filter model suggests that core effects of psychedelics may result from gating deficits, based on a

191 How psychedelics mediate their actions-both therapeutic and

192 and there is some enthusiasm about combining psychedelic medications with evidence-based psychotherap

193 the globe contemplate approval of the first psychedelic medicines, many questions remain about their

194 to 1.33), and older age and previous use of psychedelics (metaregression coefficient 0.13, 95% CI 0.

195 Classic psychedelics might be associated with lowered odds of su

196 Clinical research has shown that psychedelics might have enduring effects on mood and wel

197 them, 541 participants reported past use of psychedelics, most of whom (535 of 541 [99%]) also repor

198 and by 19.20 +/- 20.05% in mice treated with psychedelic mushroom extract (n = 16) (p = 0.001 for eff

199 from the psilocybin group and none from the psychedelic mushroom extract group.

200 e.g., "sad", "joy"), the imagination (e.g., "psychedelic", "mysterious"), profundity (e.g., "disgust"

201 In this study, 32 psychedelic-naive healthy participants from a double-bli

202 as the parent PSYCHE pure shift experiment, PSYCHEDELIC offers a robust method for chemists seeking

203 yltryptamine (DMT - a fast-acting tryptamine psychedelic) offers a safe and powerful means of advanci

204 nsible for the acute and enduring effects of psychedelics on behavior.

205 stigate potential causal pathways of classic psychedelics on cardiometabolic diseases.

206 current empirical evidence of the effects of psychedelics on creativity.

207 we review recent findings on the effects of psychedelics on emotion, emotional empathy, and mood.

208 ies paint a complex picture of the impact of psychedelics on emotions and mood.

209 Here, we describe the effects of psychedelics on neuronal physiology, highlighting their

210 However, the effects of low doses of classic psychedelics on reward processing have not been studied.

211 y to quantitively investigate the effects of psychedelics on sexual functioning.

212 Among those >= 65, classic psychedelic-only use was also associated with higher odd

213 Classic psychedelic-only users had higher odds of prostate cance

214 ively, this review provides a deep dive into psychedelic pharmaconeuroimaging studies with a core foc

215 ngs suggest that the sustained occurrence of psychedelic phenomenology constitutes an elevated level

216 mprehensive and scalable solution to enhance psychedelic preparedness, aligning with the broader shif

217 esign was informed by a four-factor model of psychedelic preparedness, using a person-centred approac

218 ience, unpleasant acute experiences (classic psychedelics), prior psychological vulnerabilities, high

219 Here we describe psychedelic (psc), a new mutant of maize (Zea mays) that

220 ve serotonin 2A receptor agonist and classic psychedelic psilocin.

221 Classic psychedelics (psilocybin, peyote, mescaline, LSD) have b

222 a preliminary report that the tryptaminergic psychedelic, psilocybin, may reduce symptoms in patients

223 type (primary or secondary), previous use of psychedelics, psilocybin dosage, type of outcome measure

224 orks, consistent with previous findings that psychedelics reduce network modularity or between-networ

225 esults support a recent model proposing that psychedelics reduce the 'precision-weighting of priors',

226 neuroimaging investigations have found that psychedelics reduce the functional segregation of large-

227 be several hypotheses that might explain how psychedelics rescue neuropsychiatric disease symptoms, a

228 hese contextual variables' known importance, psychedelic research has lacked methodological rigor in

229 actors, we aim to improve the reliability of psychedelic research in uncovering the therapeutic benef

230 in the mid-1960s effectively ended all major psychedelic research programs.

231 ions on the promises and pitfalls of renewed psychedelic research, with a focus on the development of

232 0s, there has been a steady revival of human psychedelic research: last year saw reports on the first

233 dings suggest that the subjective effects of psychedelics result from a desynchronization of ongoing

234 treatments for OUD, including cannabinoids, psychedelics, sedative-hypnotics, and immunotherapeutics

235 s independently listed potentially important psychedelic setting variables.

236 Functional plasticity was evident for both psychedelics several months after treatment, and Layer 5

237 tion in associative regions may underlie the psychedelic state and pinpoint the critical role of the

238 that these measures have been applied to the psychedelic state and, crucially, that they have yielded

239 us understand the mechanisms underlying the psychedelic state and, more generally, the pharmacologic

240 reater influence on visual processing in the psychedelic state, thereby defining its hallucinatory qu

241 tion from normal waking consciousness to the psychedelic state.

242 What is the level of consciousness of the psychedelic state?

243 he loss of consciousness and enhanced during psychedelic states.

244 ositive affective and social consequences of psychedelic substance use in naturalistic settings.

245 ited Kingdom, we investigated the effects of psychedelic substance use on transformative experience,

246 other psychoactive substances, we found that psychedelic substance use was significantly associated w

247 Anecdotal evidence has indicated that psychedelic substances may acutely enhance creative task

248 Past research suggests that use of psychedelic substances such as LSD or psilocybin may hav

249 ticularly pronounced for those who had taken psychedelic substances within the last 24 h (compared to

250 owing interest in the therapeutic utility of psychedelic substances, like psilocybin, for disorders c

251 red states of consciousness induced by three psychedelic substances: psilocybin, ketamine and LSD.

252 rest has emerged in ultra-fast, short-acting psychedelics such as 5-methoxy-N,N-dimethyltryptamine (5

253 Research on psychedelics such as lysergic acid diethylamide (LSD) an

254 Pilot studies have hinted that serotonergic psychedelics such as psilocybin may relieve depression,

255 y the long-lasting antidepressant effects of psychedelics such as psilocybin, but beyond that, the mo

256 Classical psychedelics such as psilocybin, lysergic acid diethylam

257 'Classic' serotonergic psychedelics, such as psilocybin and lysergic acid dieth

258 Plant-based psychedelics, such as psilocybin, have an ancient histor

259 In contrast to psychedelics, TBG does not induce an immediate glutamate

260 A single dose of psilocybin, a psychedelic that acutely causes distortions of space-tim

261 ory and consciousness-altering properties of psychedelics that inform on how they can model certain p

262 e with advanced stages of disease, including psychedelic therapy.

263 he acute anxiolytic action of a serotonergic psychedelic to 5-HT(2A) receptors in the ventral hippoca

264 ions of these results for the application of psychedelics to mood and stress disorders are discussed.

265 their children may be uniquely vulnerable to psychedelic treatment during the postpartum period.

266 e approach within the potential framework of psychedelic treatment.

267 nce arm changed from placebo response in the psychedelic trials to antidepressant trials.

268 However, no psychedelic trials to date have substantiated this findi

269 ost psychedelics were better than placebo in psychedelic trials, only high dose psilocybin was better

270 for selecting suitable control conditions in psychedelic trials.

271 abuse liability, and the essentiality of the psychedelic "trip" and psychological support are, inter

272 ptamine (5-MeO-DMT) is a naturally occurring psychedelic tryptamine.

273 re we tested whether lifetime use of classic psychedelics (tryptamine, lysergamide, and phenethylamin

274 significant interactions were found between psychedelic use and genetic vulnerability to schizophren

275 At the same time, the association between psychedelic use and manic symptoms seems to be associate

276 ally evaluated the associations between past psychedelic use and psychotic or manic symptoms at age 1

277 In particular, the link between psychedelic use and psychotic symptoms has been debated

278 lyses found significant associations between psychedelic use and schizotypal traits.

279 o further elucidate the link between classic psychedelic use and STBs in youth.

280 ority participants, the associations between psychedelic use and suicidality were far fewer.

281 Classic psychedelic use might be beneficial for cardiometabolic

282 l participants with positive expectations of psychedelic use might bias treatment outcomes.

283 indings from Pisano et al. who found classic psychedelic use to be linked to lowered odds of OUD in a

284 Exclusive classic psychedelic use was associated with increased odds of pr

285 tical need for trauma-informed approaches to psychedelic use, stressing appropriate preparation, supp

286 , consciousness, and free-will, change after psychedelic use.

287 ed receiving new psychiatric diagnoses after psychedelic-use and all fifteen reported the occurrence

288 ade or pre-existing symptoms made worse post psychedelic-use-and inviting these individuals to partic

289 eported greater well-being than both classic psychedelic users (n = 18,138) and non-psychedelic drug-

290 orted less problematic drinking than classic psychedelic users, although both groups reported greater

291 s and less problematic drinking than classic psychedelic users.

292 In classic psychedelics users, symptoms reduction was associated wi

293 Although most psychedelics were better than placebo in psychedelic tri

294 systematic review and meta-analysis, classic psychedelics were generally well tolerated in clinical o

295 Cannabis and psychedelics were highest-rated for improving ED symptom

296 In a sample of 174 participants, classic psychedelics were reported as the only substances effect

297 Acceptance of ultra-fast, short-acting psychedelics will depend on future randomized, placebo-c

298 -4-iodoamphetamine (DOI) is a phenethylamine psychedelic with high affinity for 5-HT(2) receptors.

299 fects relative to published reports of other psychedelics, with a short duration of action, relative

300 erved acute effects of psilocybin and other 'psychedelics' yet were related to clinical outcomes.